Bolt Biotherapeutics, Inc. — Director's Dealing 2021

Feb 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Bolt Biotherapeutics, Inc. (BOLT)
CIK: 0001641281
Period of Report: 2021-02-09

Reporting Person: Vivo Capital VIII, LLC (10% Owner)
Reporting Person: Vivo Capital Fund VIII, L.P. (10% Owner)
Reporting Person: Vivo Capital Surplus Fund VIII, L.P. (10% Owner)
Reporting Person: Vivo Panda Fund, L.P. (10% Owner)
Reporting Person: Vivo Panda, LLC (10% Owner)
Reporting Person: Vivo Opportunity Fund, L.P. (10% Owner)
Reporting Person: Vivo Opportunity, LLC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-09	Common Stock	C	944056	—	Acquired	958341	Indirect
2021-02-09	Common Stock	C	472296	—	Acquired	1430637	Indirect
2021-02-09	Common Stock	X	17711	$0.07	Acquired	1448348	Indirect
2021-02-09	Common Stock	S	62	$20.00	Disposed	1448286	Indirect
2021-02-09	Common Stock	C	1092080	—	Acquired	1117184	Indirect
2021-02-09	Common Stock	C	317922	—	Acquired	1435106	Indirect
2021-02-09	Common Stock	C	345568	—	Acquired	1780674	Indirect
2021-02-09	Common Stock	X	40953	$0.07	Acquired	1821627	Indirect
2021-02-09	Common Stock	S	144	$20.00	Disposed	1821483	Indirect
2021-02-09	Common Stock	P	175733	$20.00	Acquired	1997216	Indirect
2021-02-09	Common Stock	C	150802	—	Acquired	154268	Indirect
2021-02-09	Common Stock	C	43901	—	Acquired	198169	Indirect
2021-02-09	Common Stock	C	47718	—	Acquired	245887	Indirect
2021-02-09	Common Stock	X	5655	$0.07	Acquired	251542	Indirect
2021-02-09	Common Stock	S	20	$20.00	Disposed	251522	Indirect
2021-02-09	Common Stock	P	24267	$20.00	Acquired	275789	Indirect
2021-02-09	Common Stock	P	150000	$20.00	Acquired	150000	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-09	Series A-1 Preferred Stock	$	C	944056	Disposed		Common Stock (944056)	Indirect
2021-02-09	Series B Preferred Stock	$	C	472296	Disposed		Common Stock (472296)	Indirect
2021-02-09	Warrant (Right to Buy)	$0.07	X	17711	Disposed	2028-07-26	Common Stock (17711)	Indirect
2021-02-09	Series B Preferred Stock	$	C	1092080	Disposed		Common Stock (1092080)	Indirect
2021-02-09	Series C-1 Preferred Stock	$	C	317922	Disposed		Common Stock (317922)	Indirect
2021-02-09	Series C-2 Preferred Stock	$	C	345568	Disposed		Common Stock (345568)	Indirect
2021-02-09	Warrant (Right to Buy)	$0.07	X	40953	Disposed	2028-07-26	Common Stock (40953)	Indirect
2021-02-09	Series B Preferred Stock	$	C	150802	Disposed		Common Stock (150802)	Indirect
2021-02-09	Series C-1 Preferred Stock	$	C	43901	Disposed		Common Stock (43901)	Indirect
2021-02-09	Series C-2 Preferred Stock	$	C	47718	Disposed		Common Stock (47718)	Indirect
2021-02-09	Warrant (Right to Buy)	$0.07	X	5655	Disposed	2028-07-26	Common Stock (5655)	Indirect

Footnotes

F1: The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of
the Issuer's initial public offering (the "IPO") and had no expiration date.

F2: The securities reported herein are held of record by Vivo PANDA Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D. is one of four voting members of Vivo LLC.

F3: The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date.

F4: Upon closing of the Issuer's IPO, Vivo LP exercised a warrant to purchase 17,711 shares of the Issuer's Common Stock at an exercise price per share of $0.07. Vivo LP paid the exercise price on a cashless basis, resulting in the Issuer withholding 62 share subject to the warrant in order to pay the exercise price and issuing to Vivo LP the remaining 17,649 shares of Common Stock.

F5: The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC.

F6: The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date.

F7: The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date.

F8: Upon closing of the Issuer's IPO, Vivo Capital Fund VIII, L.P. exercised a warrant to purchase 40,953 shares of the Issuer's Common Stock at an exercise price per share of $0.07. Vivo Capital Fund VIII, L.P. paid the exercise price on a cashless basis, resulting in the Issuer withholding 144 share subject to the warrant in order to pay the exercise price and issuing to Vivo Capital Fund VIII, L.P. the remaining 40,809 shares of Common Stock.

F9: The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC.

F10: Upon closing of the Issuer's IPO, Vivo Capital Surplus Fund VIII, L.P. exercised a warrant to purchase 5,655 shares of the Issuer's Common Stock at an exercise price per share of $0.07. Vivo Capital Surplus Fund VIII, L.P. paid the exercise price on a cashless basis, resulting in the Issuer withholding 20 share subject to the warrant in order to pay the exercise price and issuing to Vivo Capital Surplus Fund VIII, L.P. the remaining 5,635 shares of Common Stock.

F11: The shares are held of record by Vivo Opportunity Fund, L.P. (VOF). Vivo Opportunity, LLC is the general partner of VOF and has four managing members.

F12: The shares subject to this warrant were fully vested prior to exercise.